News Incyte's PD-1 drug brings immunotherapy to anal cancer Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer
News Pathos AI's big $365m Series D, and other bio financings Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
News MSD adds new indication for Welireg in rare tumours MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
News AbbVie bags first approval for cancer ADC Emrelis AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis.
Oncology The mesenchymal stem cell’s superpower: Hacking the TME What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) could disrupt this shield.
News GSK pays $1.2bn for liver drug as it culls TIGIT programme GSK decided to abandon a TIGIT-targeted drug for cancer this week, then hatched a plan to replace it with a candidate for liver disease MASH.
News AI specialists Enveda and Basecamp rake in the cash AI-powered drug discovery companies Enveda and Basecamp have completed impressive funding rounds, worth $311m and $140m, respectively.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
